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ABSTRACT
Objective: Antimicrobial resistance is a growing problem in Helicobacter pylori eradication which is a microaerophilic bacterium causing various 
gastroduodenal diseases. The present study has been designed to test the efficacy of Morinda coreia against the metronidazole clarithromycin and 
levofloxacin-resistant H. pylori strains isolated from the biopsy taken from the patient suffering from gastric erosion in Guwahati, Assam.
Method: The antimicrobial activity of n-hexane and chloroform extract of M. coreia was tested against multidrug-resistant H. pylori isolate of Guwahati, 
Assam, by agar well method and microdilution method.
Result: In the present study, the H. pylori strain resistant for metronidazole (minimal inhibitory concentration [MIC] >64 µg/mL), clarithromycin at 
(MIC >0.5 µg/mL), and levofloxacin at (MIC >1 µg/mL) was tested against the n-hexane and chloroform extract of M. coreia. Both the extracts of M. 
coreia showed good efficacy against the multidrug-resistant strain of H. pylori shown inhibition at 1.2 µg/mL with n-hexane extract and 2 µg/mL with 
chloroform extract of M. coreia.
Conclusion: The prevalence of metronidazole-resistant ranges between 50% and 90% in the developing countries, including India, clarithromycin 
ranges from 0% to 15% in India, and levofloxacin ranges between 50% and 70% in India, so there is a need of alternative therapy for the eradication 
of this bacterium from the stomach. Hence, this study suggests that M. coreia, which has been used traditionally as a folk medicine for the treatment 
of many gastric diseases, has also shown good efficacy against the multidrug-resistant H. pylori strain of North-east India.
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INTRODUCTION
The Gram-negative, microaerophilic gastric bacteria Helicobacter 
pylori is recognized as an important human pathogen and classified 
as a Group I carcinogen by the International Agency for Research on 
Cancer [1]. H. pylori has infected over half of the world’s population, 
and its infection usually occurs in early childhood and can persist 
throughout a lifespan if it is untreated with a specific antibiotic regimen 
[2]. H. pylori infections are largely asymptomatic, but the studies have 
also shown that, if its association lasts for long term with the host, it 
can cause more serious disease such as gastritis, peptic ulcer, gastric 
cancer, gastric adenocarcinoma, and mucosa-associated lymphoid tissue 
lymphoma [3,4]. H. pylori eradication from the infected individuals is the 
best and only choice for an effective treatment of its associated diseases. 
Eradication by triple therapy regimen consists of a proton-pump 
inhibitor in combination with two antibiotics, such as clarithromycin 
and amoxicillin or metronidazole, which has been recommended as the 
first-line therapy and results in a high eradication rate [5]. The other 
antibiotics which are also used for the eradication of H. pylori as a 
second-line therapy or third-line therapy are levofloxacin, furazolidone, 
and tetracycline. Due to the use of these antibiotics for the treatment 
of other diseases like respiratory, anaerobic infection, dental infection, 
which have resulted in the emergence of antibiotic resistance which 
may be the major cause of treatment failure [6,7]. Metronidazole and 
clarithromycin are the most commonly used antibiotics in the treatment 
of H. pylori infection as compared to other antibiotics, but many studies 
from India and abroad have reported that the resistance for both the 
antibiotics has been increasing nowadays which may be the reason for 
the treatment failure [8-10]. The prevalence of dual drug resistance and 
multidrug resistance has been observed in many countries which has 
also become the major obstacle in the treatment for H. pylori infection. 
In the geographical areas where the resistance rate ranges between 15% 
and 90%, there is an urgent need to develop new treatment strategies 
for H. pylori infection. Unlike synthetic drugs, bioactive natural products 
which are benefical without any side effects as they are part of our day 
to day life and other culinary items [11]. In this search, Morinda coreia 
which is generally found in dry forests of the greater part of India and Sri 
Lanka belongs to the family Rubiaceae, which is one of the largest and 
the most widely distributed plants in approximately 400 genera in this 
family. M. coreia is also known by its Tamil name as “Nuna.” The plant is 
small- to medium-sized tree with a straight cylindrical stem 3.6–4.2 m 
in length and 90 cm in width [12,13]. However, it has been shown that 
the beverage produced by fermenting the fruits was able to inhibit 
enteropathogenic bacteria and also had a high amount of potassium. 
It is also extensively used in Thai traditional medicine to cure stomach 
infection and blood stasis [14]. A dye obtained from the root bark is used 
for coloring linen and woolen goods [14]. Studies have conducted using 
extracts of M. coreia against various Gram-negative and Gram-positive 
pathogenic bacteria but not with H. pylori [15]. Therefore, in the present 
study, we tested the antimicrobial activity of M. coreia against the 
multidrug-resistant strain of H. pylori isolated from the patient suffering 
from gastric erosion in North-East India.
METHODS
Source of plant material
Healthy leaves of M. coreia were collected from Sivakasi, Tamil Nadu, 
India. The leaves of M. coreia were authenticated at the Botany 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Department of Amity University. The leaves were washed properly 
under running tap water and then rinsed in distilled water. Then, it was 
air dried in the shade and grinded into powder using mortar and pestle.
Extract preparation of M. coreia
To obtain the extract of M. corea, 100 g of leaves was crushed with 
mortar and pestle and sieved. The dried powder was then extracted 
with 400 mL of n-hexane, chloroform, methanol, water, and ethanol 
consecutively for 72 h solvent under constant stirring. The extract was 
then filtered and dried under pressure and resuspended in the solvents. 
The concentrated extract was then kept in the dark bottles at 4°C until 
used. The n-hexane and chloroform extracts of M. coreia were used in 
the present study to test the antimicrobial activity against multidrug-
resistant H. pylori isolates from North-East India.
Isolation of H. pylori strains and culture
The patient suffering from gastric erosion was included in the study. The 
H. pylori strains were isolated from the antral biopsies of the patient who 
underwent endoscopy procedure in the Gastroenterology Department 
of Gauhati Medical College, Guwahati, Assam. The identification of the 
H. pylori was done on the basis of colony morphology, gram staining, 
and positive reaction in the biochemical test (catalase, urease, and 
oxidase). H. pylori strain was isolated and cultured on brain heart 
infusion (BHI) agar (Difco Laboratories, Detroit, MI) supplemented with 
5% horse serum (Invitrogen, NY), 0.4% IsovitaleX (Becton Dickinson, 
MD), trimethoprim (5 μg/mL), vancomycin (8 μg/mL), and polymixin B 
(10 μg/mL). The plates were incubated at 37°C under microaerophilic 
condition (5% O2, 10% CO2, and 85% N2) (Double gas incubator, Hera 
cell 150i) for 3–6 days. Stock cultures were maintained until use at 
–80°C in BHI broth with 20% glycerol.
Suspension preparation of H. pylori strain
The bacterial suspension of H. pylori was prepared by direct colony 
method [16]. The colonies were taken directly from the plate and were 
suspended in 5 mL of sterile 0.85% phosphate buffer saline (PBS). The 
turbidity of the initial suspension was adjusted by comparing with 
McFarland’s standard number 2 (which contains about 1×108 colony-
forming units (CFU)/mL) [17].
Antimicrobial susceptibility and resistance determination
Exponentially grown H. pylori cells on antibiotic-free BHI agar were 
further suspended in PBS buffer, 10-fold serial dilution of these cell 
suspensions was prepared, and 10 μL of each dilution was spotted 
on freshly prepared BHI agar containing various concentrations of 
different antibiotics in μg/mL, namely metronidazole (0.2, 0.5, 1.5, 3, 8, 
16, 32, and 64), clarithromycin (0.125, 025, 1, and 2), furazolidone (0.2, 
0.5, 1, and 2), amoxicillin (0.125, 0.25, 1, and 2), levofloxacin (0.2, 0.4, 1, 
and 2), and tetracycline (1, 2, 3, and 4).
Determination of minimum inhibitory concentration (MIC) by 
agar dilution method
The antibiotics plates with H. pylori cultures were incubated for 72 h 
under microaerophilic conditions; the MIC was defined as the lowest 
concentration that inhibited visible growth of organisms. The H. pylori 
isolates are considered to be resistance if the MIC for different antibiotics 
is metronidazole (>8 μg/mL) [18], clarithromycin (>0.5 μg/mL) [18], 
amoxicillin (>0.12 μg/mL) [18], tetracycline (>1 μg/mL) [18], 
levofloxacin (>1 μg/mL) [18], and furazolidone (>2 μg/mL) [17].
Conformation of antibiotic resistance by sequence analysis of 23S 
rRNA, gyraseA, rdx, and frx genes of H. pylori isolate
Antibiotic-resistant strain by agar dilution method was further 
confirmed by polymerase chain reaction (PCR) followed by sequencing 
for the amplification of 23S rRNA, gyraseA, rdx, and frx gene mutations 
responsible for the resistance of clarithromycin, levofloxacin, and 
metronidazole, respectively. Genomic DNA was isolated from the H. 
pylori strain by C-TAB method [19], and the total DNA concentration was 
determined by NanoDrop 1510 (IS10-03571C, Multiskan GO, Thermo 
Fisher Scientific). The PCR for 23S rRNA, gyraseA, rdx, and frx gene was 
performed to detect the resistance for all the antibiotics. All the genes 
were amplified using the primer sets as listed in Table 1. The PCR was 
carried out in 20 µL reaction containing 10 pmol dNTP (Bangalore 
Genei, Bengaluru, India), 10 pmole primer sets (Sigma-Aldrich), 1.5U 
Taq DNA polymerase (Bangalore Genei), and 10 ng of H. pylori-positive 
genomic DNA Eppendorf Thermocycler (vapo.protectTM) for 35 cycles 
under the following cycling conditions 94°C for 1 min, annealing 
for 1 min, and 72° for 1min. The product was finally analyzed in 2% 
agarose gel stained with ethidium bromide under standard procedure. 
All the amplified PCR products were further purified by QIAquick PCR 
Purification kit (QIAGEN, Hilden, Germany). The purified products were 
further sequenced by ABI sequencer 3100XL consisting of Big DyeR 
Terminator (PerkinElmer) with Ampli Taq FS. The sequence was edited 
after aligning with SeqMan program (DNASTAR Inc., Madison, WI). For 
the detection of point mutation in various genes of H. pylori, multiple 
sequence alignment was performed by CLUSTAL OMEGA taking 26695 
strains of H. pylori as a reference strain.
Anti-H. pylori activity of M. coreia against multidrug-resistant 
strain
MIC determination by the agar well method
The different concentration of n-hexane and chloroform extract of 
M. coreia was loaded into the well of 6 mm in diameter in inoculated 
plates with 3 × 109 CFU of multidrug-resistant strain of H. pylori isolated 
from the patient of North-East India. The plates were kept under 
microaerophilic conditions (5% O2, 10% CO2, and 85% N2) for 2 days at 
37°C. All experiments were performed in triplicates. Pure n-hexane and 
chloroform were used as a negative control, and amoxicillin was used 
as positive control.
MIC determination by microdilution method
The 96-well microtiter plate was prepared by dispensing 80 μL of 
BHI broth into first well. A 20 μL from the stock solution of M. coreia 
extract (120 μg/mL) was added to the first well. Then, five-fold serial 
dilution was performed until 8th well. The obtained concentration 
range was from 12 μg/mL to 12 × 10−7 μg/mL. To each well, 150 μL 
of the diluted bacterial cells was added to give a final concentration 
of 3 × 109 CFU/mL. The inoculated plates were incubated at 37°C for 
72 h under microaerophilic conditions. MIC90 was defined as the lowest 
concentration of extract sample that inhibited the 90% of H. pylori cells 
when compared to control, i.e., H. pylori cells without extract sample. 
Reading was noted on the Elisa reader (Erba Lisa Scan II).
Table 1: PCR primers of 23S rRNA, gyraseA, rdx, and frx genes of H. pylori
Gene Primer sequence Size of the product References
23S rRNA F-5ˈGGCTCTTTGAGTCCTTTAGGACAA-3ˈ forward sense positions 2020-2044 of U27270)











F: Forward primer; R: Reverse primer; bp: Base pairs, PCR: Polymerase chain reaction
145
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 143-148
 Mahant et al. 
Rapid urease test (RUT)
For the microbial growth visualization, RUT was done. The basis 
of the test is the ability of H. pylori to secrete urease enzyme which 
hydrolyzes the urea to ammonia and carbon dioxide and raises the 
pH of the medium from yellow (H. pylori negative) to a pink color (H. 
pylori positive). MIC was defined as the lowest concentration of extract 
sample that prevented RUT medium color change from yellow to pink.
RESULT
One clinical isolate was included in the study from the patient 
suffering from gastric erosion. The MIC for various antibiotics, namely 
metronidazole, clarithromycin, amoxicillin, tetracycline, levofloxacin, 
and furazolidone, was determined by agar dilution method against H. 
pylori isolate of North-East India. The strain which was selected to test 
the efficacy of M. corea was multidrug resistant showing resistance 
against metronidazole at the MIC of >64 µg/mL, clarithromycin at MIC 
>0.5 µg/mL, and levofloxacin at MIC >1 µg/mL but sensitive to other 
drugs, namely furazolidone, amoxicillin, and tetracycline. The genomic 
DNA was further PCR amplified for 23S rRNA, gyraseA, rdx, and frx gene 
of H. pylori for sequencing and sequence analysis (Fig. 1a-c).
Sequence analysis of various genes of H. pylori for the conformation 
of resistance pattern
Mutation analysis of 23S rRNA gene of H. pylori for clarithromycin 
resistance
The sequence of 23S rRNA gene was aligned with the reference sequence 
U27270 using CLUSTAL OMEGA for the presence of mutation at A to G 
at 2142, A to G at 2143, and T to C at 2182 positions in the V domain of 
23S rRNA gene of H. pylori (Fig. 2). The strong association was observed 
in the agar dilution method, and sequence analysis method showed that 
the H. pylori strain resistant for clarithromycin was having a mutation at 
T to C at the 2182 position and MIC of >0.5 μg/mL.
Mutation analysis of gyraseA gene of H. pylori for Levofloxacin 
resistance:
The resistance for levofloxacin was observed due to a mutation in 
gyraseA gene of H. pylori at various amino acid positions, namely 
asparagine (N) to lysine (K) at 87 position, alanine (A) to valine 
(V) at 88 position, and aspartic acid (D) to glycine (G)/tyrosine (Y)/
asparagine (N) at 91 position. The H. pylori nucleotide sequence was 
converted to protein sequence by EXPASY TRANSLATE TOOL and was 
aligned with the reference sequence HP0701 using CLUSTAL OMEGA 
for mutation analysis. Point mutation was observed from aspartic acid 
(D) to glycine(G) at 91 position in gyraseA gene of H. pylori (Fig. 3). The 
strong association was observed in the sequence analysis method and 
agar dilution method showing MIC at >1 ug/mL for levofloxacin.
Mutation analysis of rdx and frx gene of H. pylori for metronidazole 
resistance
The resistance for metronidazole was observed by the mutation in rdx 
and frx gene of H. pylori at various amino acid positions as these gene 
are highly conserved genes of H. pylori [22]. The H. pylori nucleotide 
sequence was converted to protein sequence by EXPASY TRANSLATE 
TOOL and was aligned with the reference sequence HP0954 for rdx and 
HP0642 for frx using Clustal Omega. Point mutation was observed as 
various amino acid positions of rdx and frx gene of H. Pylori (Fig. 4a and 
b). Hence, the strong association was observed in the sequence analysis 
method and agar dilution method which has shown MIC at >64 ug/mL 
for metronidazole.
Agar well method to test the efficacy of M. coreia
Different concentration of n-hexane and chloroform extract of M. coreia 
was loaded onto the well and was air dried. 100 μL of the suspended H. 
pylori strain in PBS having McFarland 2 (1×108 CFU/mL) was spreaded 
and plated onto BHI medium. The well was made in the plate using well 
puncher and the wells were loaded with different concentrations of 
the extract. After 72 h of incubation, we found that the n-hexane and 
chloroform extract of M. coreia has anti-H. pylori activity showing the 
zone of inhibition of 7 mm at 0.4 mg/mL for n-hexane extract (Fig. 5a 
and b) and 7 mm for 2.4 mg/mL chloroform extract (Fig. 6a and b) by 
agar well method, and the MIC of M. coreia was <12 μg/mL for n-hexane 
extract and <2 μg/mL for chloroform extract against multidrug-
resistance H. pylori strain of North-East India by microdilution method 
(Fig. 7 and Table 2).
DISCUSSION
H. pylori have acquired antibiotic resistance for several antibiotics in 
the past two decades, which is the major cause of treatment failure. The 
antibiotic resistance varies geographically due to its varied use in other 
diseases for the treatment of the local population. The geographical 
resistance scenario of antibiotic resistance pattern provides a guideline 
to all the clinicians for the treatment regimen. Previous studies have 
shown that resistance toward metronidazole varies geographically 
in India such as Chandigarh (38.2%) [23], Delhi NCR (48.5%) [24], 
Lucknow (68%) [23], Hyderabad (100%) [23], Chennai (82.2%), [23], 
Kolkata (85%) [8], Gangetic belt of North India (100%) [25], and 
Gujarat (83.2%) [26]. High prevalence of metronidazole was also found 
in other developing countries such as Pakistan (97.8%) [27], China 
(78.8%), Nepal (88.1%), Bangladesh (77.8%), Bhutan (83%), Vietnam 
(72%), and Mexico (76.3%) [28,29]. The resistance to metronidazole is 
Fig. 1: DNA amplification of Helicobacter pylori gene: (a) 23S rRNA 
gene of 613bp. Lane 1 - positive control, 26695 Lane 2 H. pylori 
clinical isolate,and Lane M - Marker (100bp). (b) gyraseA gene 
of 428 bp. Lane 1 - positive control, 26695 Lane 2 - H. pylori 
clinical isolate, and Lane M - Marker (100bp). (c) rdx and frx 
gene of 886bp and 780bp. Lane1 - positive control of rdx gene, 
26695 Lane 2 - H. pylori clinical isolate, Lane M - Marker (100bp), 
Lane 3 - positive control of frx gene, 26695 and Lane 4 - H. pylori 
clinical isolate
Fig. 2: Multiple sequence alignment of domain V of 23S rRNA gene of clarithromycin of Helicobacter pylori strains. The strain number is 
indicated on the left-hand side of each sequence. U27270 is a representative sequence showing T to C point mutations marked in yellow at 
positions 2182 of the 23S rRNA gene. Numbering of nucleotide position followed the proposed system by Taylor et al. (position [2515 373] 
+ 1 = position 2143)
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due to the mutation in oxygen-insensitive NADPH nitroreductase (rdx) 
and NADPH flavin oxidoreductase (frx) gene of H. pylori [22].
The resistance for levofloxacin was also reported high in many 
countries such as Delhi NCR (73.2%) [30], Gujarat (13.8%) [26], 
Bangladesh (66%), Bhutan (3%), and Vietnam (25%) [28,29]. The 
resistance for levofloxacin is due to the mutation in the amino acid 
chain of gyraseA gene of H. pylori at various positions [21]. The 
resistance to clarithromycin also observed and it is considered as one 
of the main drugs in the treatment regime in combination with proton-
pump inhibitor and amoxicillin or metronidazole. The resistance to 
clarithromycin also varies geographically such as Kolkata (0%) [8], 
Gujarat (58.8%) [26], Delhi NCR (11.8%) [31], Lucknow (4%) [23], 
Pakistan (5.4%) [27], China (12.8–23.8%), Spain (35.6), and USA 
(10–15%) [32]. Hence, the emergence of resistance to various key 
antibiotics, which are mainly used as a first-line or a second-line 
therapy in the eradication of H. pylori, has prompted us to look into the 
non-antibiotic compound that inhibits H. pylori growth.
There are many plant and plant products which are having anti-H. pylori 
effect and showed good efficacy against the drug-resistant H. pylori 
strain. De et al. showed the good efficacy of curcumin in H. pylori-
infected mouse [33]. Our other studies have shown that the methanolic 
extract of Paederia foetida [34], methanolic and ethanolic extract 
Parmelia perlata [35], Embilica officinalis [36], and methanolic and 
n-hexane extract of Brassica capitata is effective against dual and 
multidrug resistance H. pylori stain [37]. Our various studies prompted 
us to explore the efficacy of M. coreia, which is being extensively 
cultivated in India for the dye which is obtained from the root bark 
and it is a popular medicinal plant in Thailand. It has been used to 
Fig. 3: Multiple sequence alignment of gyraseA gene of Helicobacter pylori for levofloxacin resistance pattern. The strain number is 
indicated on the left-hand side of each sequence. HP0701 is a representative sequence showing D to G point mutations marked in yellow 
at amino acid positions 91 of the gyraseA gene
Fig. 4: (a) Multiple sequence alignment of rdx gene of Helicobacter pylori for metronidazole resistance pattern. The strain number is 
indicated on the left-hand side of each sequence. HP0954 is a representative sequence showing multiple point mutations marked in 
yellow at amino acid positions, (b) multiple sequence alignment of rdx gene of H. pylori for metronidazole resistance pattern. The strain 
number is indicated on the left-hand side of each sequence. HP0642 is a representative sequence showing multiple point mutations 
marked in yellow at amino acid positions
Fig. 5: (a and b) Agar well method: Antimicrobial activity of 
n-hexane extract of Morinda coreia against the multidrug-
resistant strains of Helicobacter pylori 
a b
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treat menstrual disorders, as a tonic for stomach infection and blood 
stasis, and has shown antibacterial properties against Gram-negative 
and Gram-positive bacteria [15,38]. In our study, we found that the 
n-hexane and chloroform extract of M. coreia has shown good efficacy 
against the multidrug-resistant H. pylori stain of North-East India by 
agar well method and microdilution method.
However, further research needs to be done to determine the 
compounds that are responsible for antibacterial activity against 
multidrug-resistant H. pylori strain of North-East India.
CONCLUSION
In our present study, we have primarily shown that M. coreia, which 
is a traditional plant used for the treatment of various diseases, have 
potentially inhibited the growth of multidrug-resistant H. pylori in vitro 
that were isolated from the patient suffering from gastric erosion. It is 
noteworthy that the strain was resistant for metronidazole at MIC > 
64 µg/mL, clarithromycin at MIC >0.5 µg/mL, and levofloxacin >1 µg/mL. 
Overall, this study provides novel insights in the therapeutic potential of 
n- hexane and chloroform extract of M. coreia against multidrug-resistant 
H. pylori strain, although further studies are required to determine the 
pathway of its mechanism and its active compounds.
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Fig. 6: (a and b) Agar well method: Antimicrobial activity of 
chloroform extract of Morinda coreia against the multidrug-
resistant strains of Helicobacter pylori
Fig. 7: Microdilution method: Lanes 1–8 show the 5-fold serial 
dilution of Morinda coreia extract from Lanes 1–8 with a constant 
cell count of Helicobacter pylori. Lane 9 shows the cell control 
without the extract. Lane 10 shows media control without cells. 
Lane 11 shows extract control without cells. Lane 12 shows the 
H. pylori cell control. Minimal inhibitory concentration 90 was 
observed at Lane 2 and Lane 1 for n-hexane and chloroform 
extract of M. coreia, respectively
a b
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